Galderma Group AG Overview
Pro stress-test →Galderma is a pure-play, science-based dermatology company delivering a comprehensive portfolio spanning injectable aesthetics, dermatological skincare, and therapeutic dermatology. With over 90% of sales from self-care segments paid out-of-pocket by consumers, the company is positioned to benefit from growing consumer focus on skin health and appearance globally.
Strategic Profile
Pro stress-test →Galderma leverages a specialized omnichannel go-to-market strategy supported by a dedicated salesforce of over 1,900 professionals reaching 200,000+ healthcare providers. The company's leadership position is reinforced through flagship brands including Restylane, Dysport/Azzalure, Sculptra in aesthetics and Cetaphil, Soolantra, Epiduo in dermatological care, with a robust innovation pipeline driving accelerated growth potential.
Competitive Landscape
Pro stress-test →Galderma competes in the dermatology and aesthetic markets against diversified healthcare companies and specialized dermatology players. Key competitors include Almirall (Spain-based dermatology focus), GSK (diversified pharma with dermatology portfolio), and Pierre Fabre, alongside aesthetic innovators. Galderma's pure-play focus and direct-to-consumer aesthetic segment differentiate it from broader pharmaceutical players.
Industry Context
Galderma Group AG operates in Specialty Pharmaceuticals & Dermatology.
Key facts
Founded: 1981 · Headquarters: Zug, Switzerland · Employees: 4,600 · Revenue: $4.69B · Market cap: $44.2B